Last reviewed · How we verify

d-cycloserine — Competitive Intelligence Brief

d-cycloserine (d-cycloserine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor partial agonist. Area: Psychiatry/Neurology.

marketed NMDA receptor partial agonist NMDA receptor (glycine site) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

d-cycloserine (d-cycloserine) — Massachusetts General Hospital. D-cycloserine is a partial agonist at the N-methyl-D-aspartate (NMDA) receptor glycine site, enhancing glutamatergic neurotransmission in the central nervous system.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
d-cycloserine TARGET d-cycloserine Massachusetts General Hospital marketed NMDA receptor partial agonist NMDA receptor (glycine site)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor partial agonist class)

  1. Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). d-cycloserine — Competitive Intelligence Brief. https://druglandscape.com/ci/d-cycloserine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: